Clinical trials: Ranibizumab
Retinal Vein Occlusion, Macular Edema
Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion
Antagonists of the vascular endothelial growth factor (VEGF) pathway are effective in treating macular edema resulting from retinal vein occlusion (RVO).
- Trial name
- CRAVE (NCT01428388)
- Testing
- Intravitreal injection of bevacizumab, Intravitreal injection of ranibizumab (0.5 mg per dose)
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Barnes Retina Institute
Telangiectasia
Ranibizumab in Idiopathic Parafoveal Telangiectasia (RIPT) Trial
This research is being done to look at the effects of an experimental drug, ranibizumab, for the treatment of a condition called "idiopathic parafoveal telangiectasia" or IPT.
- Trial name
- NCT00378196
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Johns Hopkins University
Visual Impairment, Macular Edema
Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO)
This clinical trial is designed to compare ranibizumab in comparison with Dexamethasone implant® after 6 months of treatment. In the study arm Lucentis will be given monthly in a pro re nata scheme whereas the comparator…
- Conditions
- Visual Impairment, Macular Edema, Central Retinal Vein Occlusion
- Trial name
- COMRADE-C (NCT01396083)
- Testing
- Ranibizumab
- Where
- 64 sites in Germany, Hungary and 2 more
- Volunteers
- 243 people
- Sponsor
- Novartis Pharmaceuticals
Retinal Vein Occlusion
Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to Retinal Vein Occlusion
This study seeks to compare dexamethasone implant with rescue intravitreal ranibizumab to monthly intravitreal ranibizumab for the treatment of macular edema secondary to branch or central retinal vein occlusion.
- Trial name
- NCT01581151
- Testing
- Dexamethasone intravitreal implant, Monthly Ranibizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Brian Burke, MPH
Choroidal Neovascularization, Retinal Pigment Epithelial Detachment
Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration
The investigators hypothesize that it is safe and effective to treat patients with choroidal neovascularisation (abnormal blood vessels growing under the retina) secondary to causes other than age related macular degeneration…
- Trial name
- NCT01628354
- Testing
- Ranibizumab
- Where
- Australia
- Volunteers
- 49 people
- Sponsor
- University of Melbourne
Glaucoma
Ranibizumab in Preventing Failure of Ahmed Valve Glaucoma Surgery
To determine whether ranibizumab therapy before and after tube insertion for glaucoma surgeries can maintain the patency of the tube and prevent scar formation, and increase the chances for a successful procedure compared to…
- Trial name
- NCT00644280
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of California, San Francisco
Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema
Ocular Safety and Usability Study for FYB201 PFS
The objective of the study is to assess the ocular safety of the FYB201 pre-filled syringe in terms of preparation and administration by Retina Specialists in the clinical setting.
- Conditions
- Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema
- Trial name
- NCT06708624
- Testing
- FYB201 0.5 mg (0.05 mL of 10 mg/mL)
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Formycon AG
Polypoidal Choroidal Vasculopathy
OCTA and Polypoidal Choroidal Vasculopathy
To investigate the structural and vascular features of choroid in patients affected by PCV after Ranibizumab intravitreal injection.
- Trial name
- NCT04714242
- Testing
- Ranibizumab Injection
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Federico II University
Diabetic Retinopathy
Study on Precision Treatment of Diabetic Retinopathy Macular Edema Guided by Real-time OCT During Operation
Select Proliferative Proliferative diabetic retinopathy(PDR) patients who are planning to undergo vitrectomy for informed notification. After obtaining informed consent, vitrectomy will be performed.
- Trial name
- NCT05138029
- Testing
- Ranibizumab Injection [Lucentis], Inner limiting membrane stripping, Dexamethasone intravitreal implant
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Affiliated Hospital of Nantong University
Diabetic Macular Edema
Ranibizumab and Bevacizumab for Diabetic Macular Edema
Background: Diabetic macular edema is a common eye complication of diabetes. It causes the blood vessels in the retina at the back of the eye to leak, causing swelling.
- Trial name
- NCT01610557
- Testing
- Ranibizumab, Bevacizumab
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 56 people
- Sponsor
- National Eye Institute (NEI)
Pterygium
Ranibizumab for the Inhibition of Neovascularization in Pterygia
The primary purpose of this trial is to evaluate the safety and tolerability of ranibizumab given via subconjunctival injection in patients undergoing pterygium surgery.
- Trial name
- NCT00768963
- Testing
- ranibizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Miami
AMD, nAMD
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD).
- Conditions
- AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
- Trial name
- ATMOSPHERE (NCT04704921)
- Testing
- ABBV-RGX-314, Ranibizumab (LUCENTIS®)
- Where
- 89 sites in United States
- Volunteers
- 671 people
- Sponsor
- AbbVie
Central Retinal Vein Occlusion
Lucentis for Macular Edema Associated With Central Retinal Vein Occlusion
The purpose of this study is to determine whether ranibizumab (Lucentis) will be effective in reducing if not eliminating the macular edema associated with the disease, central retinal vein occlusion (CRVO).
- Trial name
- NCT01028248
- Testing
- Ranibizumab (Lucentis)
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- California Retina Consultants
Macular Degeneration
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
The purpose of this study is to determine the safety and efficacy of different dosage regimens of pazopanib eye drops for the treatment of neovascular age-related macular degeneration.
- Trial name
- NCT01134055
- Testing
- pazopanib eye drops, ranibizumab intravitreal injection
- Where
- 77 sites in United States, Australia and 7 more
- Volunteers
- 510 people
- Sponsor
- GlaxoSmithKline
Proliferative Diabetic Retinopathy
Intravitreal Ranibizumab For Persistent New Vessels In Diabetic Retinopathy(Inipe Study)
To evaluate the fluorescein angiographic and visual acuity effects of a single intravitreal injection of ranibizumab for the management of persistent new vessels associated with diabetic retinopathy.
- Trial name
- INIPE (NCT00993525)
- Testing
- Intravitreal injection of ranibizumab
- Volunteers
- 22 people
- Sponsor
- University of Sao Paulo
Diabetic Macular Edema
Anterior and Posterior Segment Vascular Changes Following Laser and Anti-Vascular Endothelial Growth Factor (VEGF) Treatment of Diabetic Retinopathy
The study will investigate changes in the structure and function of blood vessels in the front and back of the eye following laser and anti-VEGF treatments for sight-threatening diabetic eye disease.
- Trial name
- VEGF (NCT01196325)
- Where
- Canada
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Visual Impairment Due to Diabetic Macular Edema
Safety and Efficacy of Ranibizumab in Diabetic Macular Edema
This study was designed to confirm the efficacy and safety of laser photocoagulation as adjunctive therapy to ranibizumab 0.5 mg versus laser monotherapy in patients with visual impairment due to Diabetic Macular Edema.
- Trial name
- RELATION (NCT01131585)
- Testing
- Active laser photocoagulation, Ranibizumab 0.5 mg
- Where
- 34 sites in Germany
- Volunteers
- 128 people
- Sponsor
- Novartis Pharmaceuticals
Choroidal Neovascularization, Age-related Macular Degeneration
Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
The purpose of this study is to evaluate the safety, biological activity and pharmacodynamic effect of repeated intravitreal doses of hI-con1 0.3 mg administered as monotherapy and in combination with ranibizumab 0.5 mg compared…
- Trial name
- EMERGE (NCT02358889)
- Testing
- hI-con1, ranibizumab
- Where
- 48 sites in United States
- Volunteers
- 88 people
- Sponsor
- Iconic Therapeutics, Inc.
Diabetic Retinopathy, Glaucoma, Neovascular
Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma
To determine the efficacy of intravitreal ranibizumab injection as adjuvant therapy in the treatment of postvitrectomy diabetic vitreous hemorrhage (PDVH) accompanied by neovascular glaucoma (NVG) as a means of preventing…
- Trial name
- NCT02647515
- Testing
- ranibizumab
- Volunteers
- 18 people
- Sponsor
- Ruijin Hospital
Proliferative Diabetic Retinopathy
25-G Vitrectomy With Ranibizumab or Triamcinolone Acetonide on PDR in China-Randomized Clinical Trial
Proliferative diabetic retinopathy(PDR) is the leading cause of visual loss in diabetic patients. Operation is an efficient method to treat PDR.
- Trial name
- aiRTo-PDR (NCT02447185)
- Testing
- Ranibizumab, Triamcinolone Acetonide
- Where
- China
- Volunteers
- 200 people
- Sponsor
- JUNYAN ZHANG